Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 10 of 59, showing 10 Applications out of 581 total, starting on record 91, ending on 100

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

91.

ECCT/16/05/02   Monitoring Pre-exposure Prophylaxis for Young Adult women (MPYA)
    Next generation real-time monitoring for PrEP adherence in young Kenyan women   
Principal Investigator(s)
1. Nelly Rwamba Mugo
Site(s) in Kenya
1. Thika Partners Study Clinic (Partners in Health Research and Development) (Kiambu county)
2. Partners in Prevention, Kisumu Site (Kisumu county)
 
07-09-2016 View

92.

ECCT/22/09/04   SAPPHIRE STUDY
    A Multisectoral Strategy to Address Persistent Drivers of the HIV Epidemic in East Africa   
Principal Investigator(s)
1. Elizabeth Anne Bukusi
Site(s) in Kenya
KEMRI-SEARCH SAPPHIRE
 
09-12-2022 View

93.

ECCT/16/12/03   The Partners Scale-Up Project
    An implementation project to scale-up delivery of antiretroviral-based HIV-1 prevention among Kenyan HIV-1 serodiscordant couples   
Principal Investigator(s)
1. Nelly Rwamba Mugo
Site(s) in Kenya
1. Thika Level 5 Hospital, Ruiru Sub-County Hospital, Kiambu County Hospital, Kikuyu PCEA Hospital (Kiambu county)
2. Coptic Hospital, Mbagathi Hospital, St. Mary\'s Hospital, Pumwani Maternity Hospital (Nairobi City county)
3. Nyeri PGH, Karatina Sub-County Hospital, (Nyeri county)
4. Kerugoya County Hospital (Kirinyaga county)
5. Murang\'a County Hospital (Murang\'a county)
 
04-02-2017 View

94.

ECCT/16/11/02   IMPAACT P1093
    Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and AdolescentsPhase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents   
Principal Investigator(s)
1. Lucy Koech
Site(s) in Kenya
KENYA MEDICAL RESEARCH INSTITUTE/WALTER REED PROJECT HIV PROGRAME
 
28-03-2017 View

95.

ECCT/17/08/04   P1081
    A PHASE IV RANDOMIZED TRIAL TO EVALUATE THE VIROLOGIC RESPONSE AND PHARMACOKINETICS OF TWO DIFFERENT POTENT REGIMENS IN HIV INFECTED WOMEN INITIATING TRIPLE ANTIRETROVIRAL REGIMENS BETWEEN 28 AND 36 WEEKS OF PREGNANCY FOR THE PREVENTION OF MOTHER-TO-CHILD TRANSMISSION:    NICHD P1081   
Principal Investigator(s)
1. FREDRICK KIPYEGON SAWE
Site(s) in Kenya
Kenya Medical Research Institute Walter Reed Project Clinical Research Centre.
 
13-11-2017 View

96.

ECCT/18/10/02   Single-dose HPV catch-up vaccination efficacy: A blinded, randomized study of single-dose HPV vaccination among adolescent girls and young women in Kenya
            Single-dose HPV catch-up vaccination efficacy: A blinded, randomized study of single-dose HPV vaccination among adolescent girls and young women in Kenya    
Principal Investigator(s)
1. Dr. Nelly Rwamba Mugo
2. Dr. Maricianah Atieno Onono
3. Prof Bukusi Anne Bukusi
4. Dr. Betty Wanjiru Njoroge
5. Dr. Ruanne Barnabas
Site(s) in Kenya
1. KEMRI NAIROBI (Nairobi City county)
2. KEMRI KISUMU (Kisumu county)
3. KEMRI THIKA PHRD (Kiambu county)
 
19-11-2018 View

97.

ECCT/13/04/03   HIV-Malaria Study_A5297
        An Open-Label, Proof of Concept, Randomized Trial Comparing a LPV/r-Based to an nNRTI-Based Antiretroviral Therapy Regimen for Clearance of    Plasmodium falciparum Subclinical Parasitemia in HIV-infected Adults with CD4+ Counts >200 and <350 cells/mm3 .   
Principal Investigator(s)
1. Josphat K. Kosgei
Site(s) in Kenya
1. Kemri Walter Reed Project-Kericho (Kericho county)
2. Moi University Clinical Research Centre (Uasin Gishu county)
 
26-03-2013 View

98.

ECCT/19/03/02   PREVENT TD
    A Randomized, Placebo-Controlled, Double-Blind, Clinical Trial Evaluating Two Dose Regimens of Rifaximin (550 mg daily or 550 mg twice daily) for Chemoprophylaxis Against Travellers’ Diarrhoea (TD) Among Active Duty Deployed U.S. and British Military Personnel (PREVENT TD)   
Principal Investigator(s)
1. Flynn Alexander
Site(s) in Kenya
Nyati Barracks, British Army Training Unit, Kenya
 
10-06-2019 View

99.

ECCT/17/06/01   MF/PM Phase III
    An Open Label, Phase III, Randomized Controlled, Multicentre Non-Inferiority Trial to Compare Efficacy and Safety of Miltefosine and Paromomycin with Sodium Stibogluconate and Paromomycin Combination for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa       
Principal Investigator(s)
1. Jane Mbui
Site(s) in Kenya
1. Kimalel Health Centre (Baringo county)
2. Kacheliba sub-county hospital (West Pokot county)
 
04-10-2017 View

100.

ECCT/24/03/06   PHOENIx MDR-TB)
    Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx MDR-TB)   
Principal Investigator(s)
1. Dr Lucy Chepkurui Koech KOECH
Site(s) in Kenya
1. Kenya medical Research Institute/ Walter Reed Project (Kericho county)
2. Moi university clinic research Centre (Uasin Gishu county)
 
21-05-2024 View